Pfizer gets Swiss yes for Xeljanz amid EU delay
This article was originally published in Scrip
Executive Summary
Glossing over the April rejection by the CHMP of its potential blockbuster JAK inhibitor Xeljanz (tofacitinib citrate), Pfizer has announced its approval in Switzerland and several other markets for use in rheumatoid arthritis.
You may also be interested in...
Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Catabasis’s Future In Doubt After DMD Phase III Failure
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Novartis Advances Novel Kidney Disease Therapy Iptacopan
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Need a specific report? 1000+ reports available
Buy Reports